By Gokhan Ergocun
ISTANBUL (AA) - The British biopharma giant GSK completed the acquisition of clinical-stage biopharmaceutical company Aiolos Bio for some $1.4 trillion, according to a press release on Thursday.
Aiolos Bio focused on addressing the unmet treatment needs of patients with respiratory and inflammatory conditions, GSK said in a press release.
The acquisition of the firm includes "AIO-001, a potentially best-in-class, long-acting anti-thymic stromal lymphopoietin (TSLP) monoclonal antibody ready to enter phase II clinical development for the treatment of adult patients with asthma."
"AIO-001 could expand GSK’s respiratory biologics portfolio to potentially reach the 40% of severe asthma patients with low T2 inflammation," it added.
According to a purchasing deal between companies, GSK will pay $1 billion for upfront payment and "up to $400 million in certain success-based regulatory milestone payments."